Profile Provides an in-Depth Insight into the Dealmaking Activity and Interests of Biogen Idec

Business Wire, Sept 20, 2007

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c68933) has announced the addition of Biogen Idec Dealmaking Profile 2007 to their offering.

Each Company Dealmaking Profile provides an in-depth insight into the dealmaking activity and interests of one of the worlds leading biopharma companies.

Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the company's business development objectives.

The company profile is also provided with a comprehensive listing of contract documents available in the public domain. The listing is sorted by deal type - therefore co-promotion deals are listed separately to licensing, M&A and supply deals, and so on.

Company Dealmaking Profiles provide the user with the following key benefits:

* Get ahead of your competitors by understanding and contacting the best partners of choice.

* Identify prospective partner companies by analyzing their dealmaking activity and interests.

* Undertake initial due diligence to assess suitability of partner companies.

* Make direct contact with named business development executives within the company.

* Review actual contract agreements entered into by the company and its partner companies.

* Understand the key deal terms the company has agreed in previous deals.

Report scope

Company Dealmaking Profiles are intended to provide business development executives, senior management and investors with decision-critical intelligence on a prospective partner's activities, interests and actual agreement contracts as signed by the company and its partners.

Each Company Dealmaking Profile includes:

* Company contact details - named contacts with their direct contact information

* Subsidiary companies

* Primary therapy areas

* Business development contacts

* Company description

* Marketed therapeutic indications

* Pipeline (phase I-III) therapeutic indications

* Partnering interests

* Partnering interests - therapeutic indications

* Partnering frequency per annum - 2000-2006

* Current partner companies (2005-6)

* Recent deals 2005-2006

* By deal type

* By stage of development

* By therapy area

* Contract documents available online 2005-2006 - link direct to each document

Each contract document is accessible through a link to an online version of the actual contract document as filed with the Securities Exchange Commission. Analyzing actual company agreements allows assessment of the following:

* What is actually granted by the agreement to the partner company?

* What exclusivity is granted?

* What is the payment structure for the deal?

* How are sales and payments audited?

* What is the deal term?

* How are the key terms of the agreement defined?

* How are IPRs handled and owned?

* Who is responsible for commercialization?

* Who is responsible for development, supply, and manufacture?

* How is confidentiality and publication managed?

* How are disputes to be resolved?

* Under what conditions can the deal be terminated?

* What happens when there is a change of ownership?

* What sublicensing and subcontracting provisions have been agreed?

* Which boilerplate clauses does the company insist upon?

* Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

* Which jurisdiction does the company insist upon for agreement law?

Report breakdown

Executive Summary

Chapter 1 - Introduction
Chapter 2 - Bigpharma - The Top 50
Chapter 3 - Most active bigpharma dealmakers
Chapter 4 - Top bigpharma deals - 2000-6
Chapter 5 - Company Profile
Chapter 6 - Resources

5 Figures also accompany this report

For more information visit http://www.researchandmarkets.com/reports/c68933